Cour Pharma Expands at ISTP
To meet the increasing demand for medical research space in the Chicagoland area, Cour Pharmaceuticals’ life science and emerging biotechnology footprint is expanding within the Illinois Science and Technology Park in Skokie, Ill. With the addition, Cour Pharmaceuticals now leases around 25,000 sq. ft. in the park.
COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression.
“Continued rapid growth for high-potential life science startups are emerging in Chicago and in addition to talent, life sciences companies like COUR will continue to need access to more specialized wet and dry lab space along with capital,” said COUR Pharmaceuticals CEO John Puisis.
